Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...
The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...
Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...
NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
Criteria used by neurologists to assess for multiple sclerosis (MS) in adults may fail to identify the illness in children with imaging suspicious for the disease, an oversight that could delay ...
NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently ...
Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...
A new study reveals that following a Mediterranean diet significantly reduces the risk of developing multiple sclerosis. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback